Figure 2. Changes in the use of lymphocyte-depleting agents and maintenance steroids during the COVID-19 pandemic; subgroup analyses.


(a) Lymphocyte-depleting agents (vs. nondepleting agent or no induction). (b) Maintenance steroids (vs. early steroid withdrawal).